Daily close, T-120 (8/2/24) through T+5. Run-up high $337.38 on 9/26/24, low $258.59 on 1/7/25 (T-120 to T-1). FDA decision 1/17/25. Historical price action, not a forecast.
Positioning before the decision
On Jan 3, 2025, 14 days before the decision date, at-the-money options priced a move of ±3.9% through Jan 24, 2025 (the first listed expiry after the decision; ATM implied volatility 20%). The stock closed +1.0% at the first close across the decision and +2.2% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Was LUMAKRAS (Sotorasib) + Vectibix (panitumumab) - (CodeBreaK 300) approved by the FDA?
Yes. The FDA approved the application for LUMAKRAS (Sotorasib) + Vectibix (panitumumab) - (CodeBreaK 300) on January 17, 2025. The primary source is linked on this page.
What was LUMAKRAS (Sotorasib) + Vectibix (panitumumab) - (CodeBreaK 300) under FDA review for?
The application covered KRAS G12C-mutated solid tumors, CRC. The FDA approved the application on January 17, 2025.
How did AMGN stock react to the FDA decision?
On the decision day AMGN moved +1.0%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.